Report Highlights

U.S. Oxygen Therapy Equipment: Market Overview

The U.S. oxygen therapy equipment market is the world's largest single-country segment, accounting for approximately 38% of global revenue in 2024. This dominance stems from a uniquely high prevalence of chronic obstructive pulmonary disease affecting 16 million diagnosed Americans, a Medicare-funded home oxygen benefit that removes cost as a primary access barrier, and a mature durable medical equipment distribution infrastructure spanning all 50 states. Unlike most global markets where hospital-based oxygen delivery dominates, the U.S. market is structurally skewed toward home and ambulatory care settings, which together represent nearly 65% of total equipment demand.

The market is organized around three principal delivery modalities: stationary oxygen concentrators, portable oxygen concentrators (POCs), and compressed or liquid oxygen systems. CMS classifies home oxygen under the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) benefit, making reimbursement policy the single most powerful commercial force in the market. The Competitive Bidding Program, administered through 130 competitive bidding areas, sets supplier payment rates and directly determines which companies can profitably serve Medicare beneficiaries. This structure creates a high-barrier, policy-driven commercial environment unlike any other major national market for this equipment category.

Growth Drivers in the U.S. Oxygen Therapy Equipment Market

Three structural demand drivers underpin sustained market expansion through 2032. First, the aging U.S. population is the most powerful force: the number of Americans aged 65 and older will exceed 73 million by 2030, per U.S. Census Bureau projections, and this cohort carries disproportionate rates of COPD, pulmonary fibrosis, and heart failure requiring supplemental oxygen. Second, the CMS Long-Term Services and Supports rebalancing initiative actively incentivizes home-based oxygen therapy over hospital stays, with bundled payment models under the Comprehensive Care for Joint Replacement program encouraging earlier hospital discharge and reliance on home oxygen support.

Third, post-COVID-19 pulmonary sequelae have permanently expanded the addressable patient population. NIH-funded research published in 2023 confirmed that approximately 3.8 million Americans experience persistent hypoxemia following severe COVID-19 infection, a substantial proportion of whom require long-term supplemental oxygen. The Veterans Health Administration separately identified oxygen therapy needs in 420,000 eligible veterans, representing a captive, federally funded demand channel. The FDA's 510(k) clearance pathway for Class II oxygen concentrators has also accelerated product innovation cycles, bringing 14 new portable device clearances between 2021 and 2024, sustaining competitive differentiation and expanding prescription volume.

Market Restraints and Entry Barriers

The CMS DMEPOS Competitive Bidding Program is the defining entry barrier for any supplier seeking Medicare revenue, which constitutes 67% of all U.S. home oxygen reimbursement. Winning a competitive bid requires demonstrating financial solvency, state-specific supplier accreditation from a CMS-approved organization such as The Joint Commission or the Accreditation Commission for Health Care, and the operational capacity to serve an entire competitive bidding area. Small entrants are systematically excluded from bids dominated by national suppliers including Lincare Holdings and Rotech Healthcare, which leverage scale economics unavailable to regional or foreign market entrants without a pre-existing U.S. distribution footprint.

Regulatory compliance costs compound the challenge. All oxygen equipment sold in the U.S. must receive FDA 510(k) clearance or premarket approval, a process averaging 12 months and costing between USD 50,000 and USD 300,000 per device. State-level licensure for home health agencies varies across all 50 jurisdictions, creating a patchwork compliance burden. Additionally, CMS reimbursement rates for stationary oxygen concentrators have declined 9.5% in real terms since the 2016 round of competitive bidding, compressing margins and making organic market entry without acquisition of an existing accredited supplier economically unattractive for most new entrants.

Market Opportunities in the U.S. Oxygen Therapy Equipment Market

The pediatric and neonatal oxygen therapy segment is materially underserved and represents a near-term addressable opportunity estimated at USD 380 million in 2024. Existing POC manufacturers have largely focused on adult COPD patients, leaving neonatal high-flow nasal cannula systems and pediatric-specific concentrators as product gaps. Vapotherm and Teleflex currently hold dominant positions in high-flow therapy, but their product lines leave ambulatory pediatric oxygen unaddressed. A manufacturer entering this sub-segment with FDA-cleared pediatric POCs gains access to hospital discharge programs operated by children's hospitals in 48 states, all of which are actively seeking home transition equipment approved for patients under 40 kg.

Telehealth-integrated oxygen management represents a second high-growth entry vector. Remote patient monitoring codes established under CPT codes 99453 and 99454 now enable providers to bill CMS for oxygen saturation monitoring data transmitted from connected concentrators. Inogen's connected platform and Invacare's remote monitoring integration demonstrate clinical traction, but the enterprise software layer linking device data to electronic health records remains fragmented. A technology entrant providing a HIPAA-compliant, EHR-agnostic oxygen monitoring platform with HL7 FHIR integration has a defined commercial path: contracting directly with large health systems and ACOs as a value-based care enabler rather than competing as a DMEPOS supplier subject to bidding constraints.

Market at a Glance

Leading Market Participants

• Lincare Holdings (Linde plc subsidiary)
• Rotech Healthcare
• Inogen Inc.
• Philips Respironics
• Invacare Corporation
• Chart Industries (Caire Inc.)
• Vapotherm Inc.
• Drive DeVilbiss Healthcare
• Nidek Medical Products
• Teleflex Incorporated

Regulatory and Policy Environment

The regulatory framework governing oxygen therapy equipment in the U.S. is administered jointly by the FDA and CMS. The FDA classifies oxygen concentrators as Class II medical devices requiring 510(k) clearance under 21 CFR Part 868, with specific performance standards referenced in ISO 80601-2-69. The CMS home oxygen benefit is codified under Section 1861(m) of the Social Security Act, with payment methodology governed by 42 CFR Part 414. The DMEPOS Competitive Bidding Program, authorized by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and operationalized through Subpart F of 42 CFR Part 414, runs in multi-year rounds. Round 2021 pricing remains in effect through 2025, with Round 2025 bidding specifications expected to be published by CMS in mid-2025.

State-level regulation requires home oxygen suppliers to obtain licensure as home health agencies or medical equipment providers, with requirements varying significantly: California's Department of Public Health mandates biennial facility inspections, while Texas HHS requires separate licensing for each branch location. The Accreditation Commission for Health Care and The Joint Commission provide CMS-approved accreditation, each requiring compliance with staffing ratios, equipment maintenance protocols, and patient education documentation. Suppliers billing Medicare must also comply with the Affordable Care Act's Section 6407 face-to-face encounter requirement, mandating physician documentation of medical necessity before oxygen prescriptions are honored. Non-compliance triggers overpayment demands and exclusion from Medicare and Medicaid programs.

Long-Term Outlook for U.S. Oxygen Therapy Equipment

By 2032, the U.S. oxygen therapy equipment market will be structurally reshaped by three converging forces: continued consolidation among DMEPOS suppliers, mandatory integration of remote monitoring into reimbursement qualification, and the maturation of wearable micro-concentrator technology. CMS is actively piloting value-based purchasing models for DME under the Innovation Center's CMMI framework, and oxygen therapy is a leading candidate for bundled payment inclusion by 2027. Suppliers that cannot demonstrate outcomes data through connected devices will face reimbursement disadvantage, making hardware-software integration a prerequisite for competitive viability rather than a differentiator.

The portable oxygen concentrator segment will account for an estimated 42% of total market revenue by 2032, displacing liquid oxygen systems as the primary ambulatory modality due to lower logistics cost, improved battery performance, and patient preference data now required by CMS for coverage decisions. Inogen's fifth-generation POC platform, launched in 2024, sets the benchmark for liter-flow range and weight that competitors must match by 2027 to retain formulary positioning with major health systems. Foreign manufacturers seeking U.S. market entry by 2032 face a closing window: supplier consolidation driven by Round 2025 competitive bidding will further entrench national incumbents, making acquisition of an accredited existing supplier the only commercially viable entry strategy within this forecast horizon.